Jeffrey Hung

A differentiated approach to gene editing has ushered a bullish sentiment from BofA Securities and Morgan Stanley on Graphite Bio, Inc. (NASDAQ: GRPH) just a few weeks after its IPO. BofA Securities on Graphite Bio Analyst Geoff Meacham initiated the firm’s coverage on Graphite with a...

Morgan Stanley has dropped its bearish stance on Exelixis, Inc. (NASDAQ: EXEL), although the research firm hasn't gained enough confidence to recommend buying the drugmaker's stock.  The Analyst Analyst Jeffrey Hung upgraded Exelixis from Underweight to Equal-weight ...

Biotech plays are numerous, and Morgan Stanley has a few recommendations to pare and prop a pharma portfolio. The Ratings Analyst Jeffrey Hung initiated coverage of: Alder Biopharmaceuticals Inc (NASDAQ: ALDR) with an Underweight rating and $19 price target; Exelixis, Inc. (NASDAQ:...

The discontinuation of Celgene Corporation (NASDAQ: CELG)’s mongerson for Crohn’s disease prompted a 6.6-percent sell-off in Friday’s premarket trading. But UBS was undeterred by the announcement. “Looking forward, we are still encouraged by the prospects for this next...